Certain Common Stock of AcelRx Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 9-JAN-2019.
January 08, 2019
Share
Certain Common Stock of AcelRx Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 9-JAN-2019. These Common Stock will be under lockup for 61 days starting from 9-NOV-2018 to 9-JAN-2019.
Details:
The officers and our directors have agreed that they will not sell, offer to sell, contract to sell or lend, pledge, hypothecate or grant any security interest in, or in any other way transfer or dispose of any shares of common stock or options or warrants or other rights to acquire common stock or any securities exchangeable or exercisable for or convertible into common stock, for a period of 60 days after the date of the underwriting agreement without the prior written consent of Credit Suisse Securities (USA) LLC and Jefferies LLC.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for use in medically supervised settings. The Companyâs nafamostat product candidates include Niyad and LTX-608. Niyad is focused on developing regional anticoagulants for injection into the extracorporeal circuit, such as the dialysis circuit during continuous renal replacement therapy (CRRT) for acute kidney injury (AKI) patients in the hospital, and for chronic kidney disease patients undergoing intermittent hemodialysis (IHD) in dialysis centers. LTX-608 is its nafamostat formulation for direct intravenous (IV) infusion being explored as an investigational product for the antiviral treatment of COVID, acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), and acute pancreatitis. Its pre-filled syringe product candidates include Fedsyra and Phenylephrine.
TALPHERA, INC. 
